Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

I just Googled "Avastin revenue" and came across a 2014 drug ranking by revenue. Avastin was #7 worldwide with $6.8 billion in sales. Wow, and just to think that the ADXS GOG cervical cancer trial produced 1-year survival better than GOG's comparable Avastin trial on cervical cancer. Stepping back and seeing the forest for the trees, ADXS holds incredible potential for investors. Triple digit prices are not that far fetched when you look at the versatility of the platform to treat numerous types of cancers like Avastin does. The hard part as an investor is in fact seeing the forest for the trees because of all the manipulation and short-term churning the trees are extremely annoying and in the way